Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on asymmetric catalytic hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102532149A details a novel asymmetric synthesis for galanthamine and lycoramine. Discover cost-effective, scalable routes for high-purity API manufacturing.
Patent CN103319311A details a high-efficiency iridium-catalyzed route for (1S)-1-(2,6-dichloro-3-fluorophenyl)ethanol, offering superior ee values and scalability for API production.
Patent CN105254474A details high-efficiency chiral citronellol production using rhodium catalysis, offering significant supply chain and cost advantages for fragrance manufacturers.
Patent CN107722068A reveals high-efficiency iridium catalysts for chiral alcohol synthesis. Discover cost reduction in pharmaceutical intermediate manufacturing and supply chain advantages.
Patent CN115160162B reveals high-efficiency chiral synthesis. Delivers superior purity and scalable supply chain solutions for global pharmaceutical intermediate manufacturing.
Novel phosphoramidite ligands offer high ee values and scalable synthesis for pharmaceutical intermediates manufacturing with significant cost advantages.
Patent CN111484533B discloses novel Ir-SpiroPNP catalysts achieving 99.8% ee in dialkyl ketone hydrogenation, offering cost reduction in pharmaceutical intermediate manufacturing.
Patent CN102532149B details a scalable asymmetric synthesis for Galanthamine. This report analyzes cost reduction in API manufacturing and supply chain reliability for pharmaceutical intermediates.
This patent details asymmetric hydrogenation for hydantoin derivatives offering high selectivity and atom economy for scalable pharmaceutical intermediate manufacturing supply chains.
This novel ruthenium catalyst method ensures high dr value and cost reduction in pharmaceutical intermediates manufacturing for reliable supply chain partners globally.
Patent CN112047856B details efficient Rh-catalyzed asymmetric hydrogenation for high-purity chiral alpha-amidoaldehydes, offering significant cost reduction and supply chain stability for pharma manufacturing.
Patent CN102304007B reveals high-ee asymmetric hydrogenation using chiral Ru catalysts enabling cost reduction in pharmaceutical intermediate manufacturing with scalable processes.
Novel phosphite ester patent CN120504699A enables mild asymmetric hydrogenation. Reduces cost and improves supply chain reliability for pharmaceutical intermediates.
Patent CN101921229B details a novel asymmetric catalytic hydrogenation route for L-Stepholidine. Discover cost-effective, scalable manufacturing solutions for high-purity pharmaceutical intermediates.
Patent CN115286504B details asymmetric hydrogenation for brivaracetam intermediate. Delivers high purity and supply chain stability for global pharmaceutical manufacturing.
Patent CN110724164B details novel pyridine-substituted spiro ligands enabling high TON hydrogenation. Ideal for API intermediates.
Patent CN110724164B discloses novel 3-substituted spiro ligands achieving 99% ee. Enables cost-effective API intermediate manufacturing with high TON.
Patent CN105111208B enables efficient asymmetric hydrogenation. Reduces costs and improves supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN100389877C details a novel PEG-supported ruthenium catalyst enabling ambient pressure asymmetric hydrogenation, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN113999207B reveals efficient synthesis of pyridyl-containing chiral NNN ligands via asymmetric hydrogenation, offering cost-effective routes for pharmaceutical intermediates.